These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 19296760)

  • 1. Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6.
    Karthikeyan G; Mehta SR; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2009 Mar; 7(3):241-9. PubMed ID: 19296760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
    Mehta SR; Boden WE; Eikelboom JW; Flather M; Steg PG; Avezum A; Afzal R; Piegas LS; Faxon DP; Widimsky P; Budaj A; Chrolavicius S; Rupprecht HJ; Jolly S; Granger CB; Fox KA; Bassand JP; Yusuf S;
    Circulation; 2008 Nov; 118(20):2038-46. PubMed ID: 18955665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.
    ; Mehta SR; Yusuf S; Granger CB; Wallentin L; Peters RJ; Bassand JP; Budaj A; Joyner C; Chrolavicius S; Fox KA
    Am Heart J; 2005 Dec; 150(6):1107. PubMed ID: 16338245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
    Mehta SR; Granger CB; Eikelboom JW; Bassand JP; Wallentin L; Faxon DP; Peters RJ; Budaj A; Afzal R; Chrolavicius S; Fox KA; Yusuf S
    J Am Coll Cardiol; 2007 Oct; 50(18):1742-51. PubMed ID: 17964037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk.
    Joyner CD; Peters RJ; Afzal R; Chrolavicius S; Mehta SR; Fox KA; Granger CB; Franzosi MG; Flather M; Budaj A; Bassand JP; Yusuf S
    Am Heart J; 2009 Mar; 157(3):502-8. PubMed ID: 19249421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial.
    Sculpher MJ; Lozano-Ortega G; Sambrook J; Palmer S; Ormanidhi O; Bakhai A; Flather M; Steg PG; Mehta SR; Weintraub W
    Am Heart J; 2009 May; 157(5):845-52. PubMed ID: 19376310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fondaparinux: an overview.
    Nadar SK; Goyal D; Shantsila E; Banerjee P; Lip GY
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):577-85. PubMed ID: 19505272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial.
    Jolly SS; Faxon DP; Fox KA; Afzal R; Boden WE; Widimsky P; Steg PG; Valentin V; Budaj A; Granger CB; Joyner CD; Chrolavicius S; Yusuf S; Mehta SR
    J Am Coll Cardiol; 2009 Jul; 54(5):468-76. PubMed ID: 19628124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fondaparinux in acute coronary syndromes.
    Chaturvedi V; Karthikeyan G
    Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1615-23. PubMed ID: 19929450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The medical management of acute coronary syndromes and potential roles for new antithrombotic agents.
    Pollack CV; Goldberg AD
    J Emerg Med; 2008 May; 34(4):417-28. PubMed ID: 18226874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.
    Mehta SR; Steg PG; Granger CB; Bassand JP; Faxon DP; Weitz JI; Afzal R; Rush B; Peters RJ; Natarajan MK; Velianou JL; Goodhart DM; Labinaz M; Tanguay JF; Fox KA; Yusuf S;
    Circulation; 2005 Mar; 111(11):1390-7. PubMed ID: 15781750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
    ; Yusuf S; Mehta SR; Chrolavicius S; Afzal R; Pogue J; Granger CB; Budaj A; Peters RJ; Bassand JP; Wallentin L; Joyner C; Fox KA
    N Engl J Med; 2006 Apr; 354(14):1464-76. PubMed ID: 16537663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes.
    Budaj A; Eikelboom JW; Mehta SR; Afzal R; Chrolavicius S; Bassand JP; Fox KA; Wallentin L; Peters RJ; Granger CB; Joyner CD; Yusuf S;
    Eur Heart J; 2009 Mar; 30(6):655-61. PubMed ID: 18713759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of fondaparinux in patients with acute coronary syndromes.
    Bassand JP; Richard-Lordereau I; Cadroy Y
    Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1013-26. PubMed ID: 18035917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Routine use of fondaparinux in acute coronary syndromes: a 2-year multicenter experience.
    Schiele F; Meneveau N; Seronde MF; Descotes-Genon V; Dutheil J; Chopard R; Ecarnot F; Bassand JP;
    Am Heart J; 2010 Feb; 159(2):190-8. PubMed ID: 20152216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enoxaparin in acute coronary syndromes.
    Lee S; Gibson CM
    Expert Rev Cardiovasc Ther; 2007 May; 5(3):387-99. PubMed ID: 17489664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial.
    Lopes RD; Alexander KP; Marcucci G; White HD; Spinler S; Col J; Aylward PE; Califf RM; Mahaffey KW
    Eur Heart J; 2008 Aug; 29(15):1827-33. PubMed ID: 18519426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of anticoagulation strategies in non-ST-elevation acute coronary syndromes.
    Maxwell CB; Holdford DA; Crouch MA; Patel DA
    Ann Pharmacother; 2009 Apr; 43(4):586-95. PubMed ID: 19336655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study.
    Simoons ML; Bobbink IW; Boland J; Gardien M; Klootwijk P; Lensing AW; Ruzyllo W; Umans VA; Vahanian A; Van De Werf F; Zeymer U;
    J Am Coll Cardiol; 2004 Jun; 43(12):2183-90. PubMed ID: 15193678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.